Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 19Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Small Cell Lung Carcinoma 1Recurrence 1Prostate Adenocarcinoma 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Follicular 1Colorectal Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bulbo-Spinal Atrophy, X-Linked 1Bites and Stings 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

Bevacizumab 11atezolizumab 8Specimen Handling 7Magnetic Resonance Spectroscopy 7Nivolumab 6durvalumab 5tremelimumab 3lenvatinib 3cabozantinib 3Ipilimumab 3ulixertinib 2tislelizumab 2relatlimab 2donafenib 2camrelizumab 2apatinib 2X-Rays 2Surgical Procedures, Operative 2Sorafenib 2Oxaliplatin 2Leucovorin 2Immunotherapy 2Fluorouracil 2Fluorodeoxyglucose F18 2trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1sonidegib 1sofosbuvir-velpatasvir drug combination 1sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × enzalutamide × 30 days × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡